Glioma Treatment Market Report 2026

The glioma treatment market size has grown strongly in recent years. It will grow from $5.37 billion in 2025 to $5.72 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to advances in neurosurgery, growth of radiation oncology, chemotherapy adoption, improved diagnostic imaging, expansion of cancer care facilities.

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to precision oncology integration, development of novel targeted drugs, improved survival outcome focus, expansion of specialty oncology clinics, personalized treatment protocols. Major trends in the forecast period include increased use of combination therapy approaches, rising focus on early surgical intervention, expansion of targeted drug therapies, growing role of radiation therapy optimization, improved long-term disease management.

The increasing demand for personalized medicine is expected to drive the growth of the glioma treatment market in the coming years. Personalized medicine is a tailored healthcare approach that considers individual patient characteristics, such as genetics, lifestyle, and environment, to enhance treatment effectiveness and clinical outcomes. This growing demand is fueled by advancements in genomics, greater patient awareness, and improved treatment efficacy. The identification of glioma-associated biomarkers helps predict patient responses to therapy, enabling the development of individualized treatment plans tailored to each patient’s unique tumor profile. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, compared to six approvals in 2022. Therefore, the rising demand for personalized medicine is driving the glioma treatment market.

Leading companies in the glioma treatment market are introducing innovative products, such as immunotherapies, to more effectively target tumors and improve patient outcomes. Immunotherapies are treatments designed to stimulate or harness the body’s immune system to identify and attack cancer cells. For example, in June 2024, Servier Pharmaceuticals, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets, representing the first targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib acts as a dual inhibitor of isocitrate dehydrogenase (IDH) 1 and 2 mutations, which are commonly present in gliomas. These mutations produce 2-hydroxyglutarate (2-HG), a metabolite that promotes tumor growth. By inhibiting these enzymes, vorasidenib reduces 2-HG levels, potentially slowing tumor progression.

In February 2023, Kite, a US-based global biopharmaceutical company, acquired Tmunity Therapeutics for an undisclosed amount. This acquisition expands and strengthens Kite's internal capabilities in cell therapy research by adding additional pipeline assets. It provides access to preclinical and clinical programs, including an ‘armored’ CAR T technology platform that could enhance the anti-tumor activity of various CAR-T therapies. Tmunity Therapeutics Inc. is a US-based biotherapeutics company developing innovative therapies for the treatment of diffuse intrinsic pontine glioma.

Major companies operating in the glioma treatment market are Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

North America was the largest region in the glioma treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glioma treatment market by increasing costs of imported oncology drugs, radiotherapy equipment, and diagnostic tools. Hospitals and specialty clinics are most affected due to reliance on imported treatment technologies. These tariffs increase treatment costs by raising expenses for radiation therapy, chemotherapy, and diagnostic monitoring. However, they encourage domestic oncology manufacturing, supporting regional production of cancer treatment equipment and drugs.

The glioma treatment market research report is one of a series of new reports that provides glioma treatment market statistics, including glioma treatment industry global market size, regional shares, competitors with a glioma treatment market share, detailed glioma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the glioma treatment industry. This glioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glioma treatment refers to therapies aimed at reducing symptoms, removing or controlling the tumor, and minimizing long-term damage to the brain or spinal cord. These treatments also target any remaining glioma cells following surgery.

The main types of glioma treatment are low-grade and high-grade. Low-grade gliomas are brain tumors that tend to grow slowly. The diseases treated include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others. Treatments are administered through various routes, including oral, parenteral, and others, and include surgical procedures, radiation therapy, chemotherapy, targeted drug therapy, and more. End users of these treatments include hospitals, specialty clinics, and other healthcare facilities.

The glioma treatment market includes revenues earned by entities by cerebral spinal fluid diversion, internal radiation therapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.